Moderna (MRNA) Tops Q4 EPS by 51c, Beats on Revenue

Moderna (NASDAQ: MRNA) reported Q4 EPS of ($2.11), $0.51 better than the analyst estimate of ($2.62). Revenue for the quarter came in at $678 million versus the consensus estimate of $662.84 million.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• UBS Assumes Interactive Brokers Group (IBKR) at Neutral, 'A Best-in-Class, Yet Fairly Valued Brokerage'
• Morgan Stanley Upgrades Mitsubishi Chemical Holdings (4188:JP) (MTLHY) to Overweight
• BTIG Upgrades Tidewater Inc (TDW) to Buy, 'Increasing Activity Set To Push Dayrates Higher in Key Basins'